mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer.
These kits are based on mtm's proprietary E6H4(TM) antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.
Funding Rounds (4) - $81.6MUpdate
Wellington Partners is a venture capital firm that invests in technology and life sciences...
Healthcare Venture Capital
As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging...
HBM BioCapital with a committed capital of $ 170 million is a Cayman Islands limited partnership...
Venture Capital Firm